Table 1.

Subject demographics and characteristics at baseline

Age, y	Diagnosis	Stage	MECP2 mutation	Concomitant medications	Breathing phenotype
3	Classic	II	R168X	None	None
7	MRD*	n/a†	C1135_1142 del	None	None
7	MRD*	n/a†	C1135_1142 del	None	None
2	Classic	II	C790_808 del	Levetiracetam	BH, HV, AE
5	Classic	III	Large del exon 3 and 4	None	BH, HV
4	Classic	III	C1159_1273 del	None	AE‡
8	Classic	III	R255X	Lamotrigine, lorazepam, melatonin	BH, AE§
4	Classic	III	R255X	None	AE
8	Classic	III	T158M	None	BH, AE§
3	MRD	n/a†	R306C	None	None
10	Classic	III	Large del exon 1 and 2	Gabapentin, diastat	BH, AE, cyanosis§
8	Classic	III	P322L	Levetiracetam	BH, AE, cyanosis§

AE, air expulsion; BH, breath holding; HV, hyperventilation.

^*Subjects did not continue in OLE.

^†Staging not applicable (n/a) to non-RTT.

^‡Subject with mild apnea (apneic episodes >10 s and <5 apneas per hour).

^§Subjects with moderate–severe apnea (apneic episodes >10 s and >5 apneas per hour).